Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ekaterine Asatiani

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Contemporary Clinical Trials Communications|July 22, 2024
Three steps toward dose optimization for oncology dose findingJason J Z Liao, Ekaterine Asatiani, Qingyang Liu, et al.
International Journal of Cancer|July 8, 2022
A hybrid design for dose-finding oncology clinical trialsJason J Z Liao, Feng Zhou, Heng Zhou, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2022
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic MalignanciesAmer M Zeidan, Rachel J Cook, Rodolfo Bordoni, et al.
Targeted Oncology|February 14, 2023
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid TumorsJames J Harding, Christiane Jungels, Jean-Pascal Machiels, et al.
The Oncologist|March 27, 2014
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment responseXiaochun Liu, Patricia Lorusso, Monica Mita, et al.
Leukemia Research|June 11, 2013
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignanciesCarlos Graux, Anne Sonet, Johan Maertens, et al.
Future Oncology (London, England)|July 18, 2020
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangementsTanios S Bekaii-Saab, Juan W Valle, Eric Van Cutsem, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Contemporary Clinical Trials Communications|July 22, 2024
Three steps toward dose optimization for oncology dose findingJason J Z Liao, Ekaterine Asatiani, Qingyang Liu, et al.
International Journal of Cancer|July 8, 2022
A hybrid design for dose-finding oncology clinical trialsJason J Z Liao, Feng Zhou, Heng Zhou, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2022
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic MalignanciesAmer M Zeidan, Rachel J Cook, Rodolfo Bordoni, et al.
Targeted Oncology|February 14, 2023
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid TumorsJames J Harding, Christiane Jungels, Jean-Pascal Machiels, et al.
The Oncologist|March 27, 2014
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment responseXiaochun Liu, Patricia Lorusso, Monica Mita, et al.
Leukemia Research|June 11, 2013
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignanciesCarlos Graux, Anne Sonet, Johan Maertens, et al.
Future Oncology (London, England)|July 18, 2020
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangementsTanios S Bekaii-Saab, Juan W Valle, Eric Van Cutsem, et al.
Pageof 1